Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 33Breast Neoplasms 17Prostatic Neoplasms 15Colorectal Neoplasms 13Hematologic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Myasthenia Gravis 4Melanoma 4Lymphoma 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma 4Pain 3Ovarian Neoplasms 3Neoplasm Metastasis 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Hematopoietic and Lymphatic System Neoplasm 3Hematologic Diseases 3Glioma 3Gastrointestinal Neoplasms 3Disease 3Colonic Neoplasms 3

Interventions

somapacitan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Dwarfism, Pituitary × 90 days × Clear all
NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Novo Nordisk A/S

Enrolling by invitation
500 enrolled
Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡